Drug Trial Radar · NCT06355531
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Jul 23, 2024
Primary completion
Oct 5, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Ferrer Internacional S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Conditions
- Progressive Supranuclear Palsy
Interventions
FNP-223Drug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 52 in the PSPRS OutcomeTime frame: Baseline to Week 52
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline to Week 52
- Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Baseline to Week 52
Locations
44 sites in 9 countries. Site status is shown where the registry gives one.
The Neurology Center of Southern California - Carlsbad
Carlsbad, California
UCSF Weill Institute for Neurosciences
San Francisco, California
Rocky Mountain Movement Disorders Center
Denver, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Augusta University
Augusta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai
New York, New York
Columbia University Irving Medical Center
New York, New York
Duke Neurology
Durham, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Central Texas Neurology Consultants
Round Rock, Texas
Groupe Hospitalier Pellegrin
Bordeaux, France
Hôpital de la Timone
Marseille, France
L'Hôpital Universitaire Carémeau
Nîmes, France
Hôpital Universitaire Pitié Salpêtrière
Paris, France
Hôpital Pierre-Paul Riquet
Toulouse, France
Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
Beelitz, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Ludwig-Maximilians-Universität München (LMU)
Munich, Germany
Pécsi Tudományegyetem Általános Orvostudományi Kar
Pécs, Hungary
IRCCS Istituto Delle Scienze Neurologiche di Bologna
Bologna, Italy
Azienda Ospedale Università di Padova
Padova, Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
Roma, Italy
Azienda Ospedaliera Universitaria San Giovanni di Dio Ruggi d'Aragona
Salerno, Italy
Neurologia Śląska Centrum Medyczne
Katowice, Poland
Mazowiecki Szpital Bródnowski w Warszawie
Warsaw, Poland
Hospital de Braga
Braga, Portugal
Campus Neurológico Senior - Torres Vedras
Torres Vedras, Portugal
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Universitario Cruces
Barakaldo, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.